Clinical Trials Browser

Phase 3 × HER2+ Metastatic Breast Cancer (MBC) × neratinib × Clear all

NCT01808573 2021-06-11

NALA

Phase 3 Completed

621 enrolled 21 charts 2 FDA

HER2+ Metastatic Breast Cancer (MBC)